Answers are grounded in this paper and cite their sources.
Observational study describes early adopters of injectable HIV therapy in Italy, highlighting key characteristics and adherence.
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.
No takes yet. Share an insight, caveat, or question.
Bartalucci et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: